Rosetta Genomics markets miRview Meso as a test “that accurately differentiates malignant pleural mesothelioma from other carcinomas in the lung and pleura.” The company just had their research corroborated in an article published this month in “The Journal of Molecular Diagnostics” that found that the test is effective for accurately diagnosing mesothelioma. According to researchers, miRview Meso is a “useful tool in the differential diagnosis of malignant pleural mesothelioma from other malignancies in the pleura.”
Pleural mesothelioma is a serious cancer caused by breathing in asbestos fibers that then become lodged in the thin membrane that lines and encases the lungs. With no known cure for mesothelioma, an emphasis is placed on early detection and treatment to minimize the impact of this deadly disease on those at-risk. Tina Edmonston, M.D., Medical Director and Head of Clinical Laboratory at Rosetta Genomics said an accurate diagnosis of mesothelioma “is important, as it guides treatment decisions.”
The study used microRNA microarrays to identify potential biomarkers. The clinical validation of this diagnostic assay was performed on 68 samples from the lung and pleura. The assay reached a sensitivity of 100% and a specificity of 94% effectively distinguishing mesothelioma from peripheral lung adenocarcinoma and metastatic epithelial cancers.
Rosetta Genomics, with offices in Israel and Philadelphia, Pennsylvania, develops diagnostic and therapeutic products based on the applications of genomics and microRNAs.
brought to you by http://blog.mesotheliomahelp.net
No comments:
Post a Comment